

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/711,775	10/04/2004	Shyam K. Gupta	, 5774	
34820 SHYAM K. G	7590 07/10/2007 UPTA	7	EXAM	INER
BIODERM RESEARCH			WESTERBERG, NISSA M	
5221 E. WIND SCOTTSDAL	PROSE DRIVE E. AZ 85254		ART UNIT	PAPER NUMBER
	-,		1609	
			MAIL DATE	DELIVERY MODE
			07/10/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

·	Application No.	Applicant(s)				
·	10/711,775	GUPTA, SHYAM K.				
Office Action Summary	Examiner	Art Unit				
	Nissa M. Westerberg	1609				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period we failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on	_•					
2a) ☐ This action is FINAL . 2b) ☐ This action is non-final.						
3) Since this application is in condition for allowan	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Disposition of Claims	·					
4) Claim(s) 1-22 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-22 are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
·	•	•				
Attachment(s)						
Notice of References Cited (PTO-892)	4) Interview Summary (Paper No(s)/Mail Da					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	atent Application					
Paper No(s)/Mail Date 6) Other:						

Application/Control Number: 10/711,775

Art Unit: 1609

DETAILED ACTION

Election/Restrictions

Claims 1 – 22 are generic to the following disclosed patentably distinct species: topical matrix metalloprotease inhibitor composition. The species are independent or distinct because as disclosed the different species have mutually exclusive characteristics for each identified species. Applicant is required to elect a species from each of the following 5 species election requirements. For the first species election requirement, claims 1 – 8 and 10 – 17 are generic. For the second species election requirement, claims 1, 9, 18 – 22 are generic. For the third species election requirement, claim 18 is generic. For the fourth species election requirement, claims 19 and 21 are generic. For the fifth species election requirement, claims 20 and 22 are generic. In addition, these species are not obvious variants of each other based on the current record.

First Species Election Requirement

Applicant is required to elect a particular compound for the matrix metalloprotease inhibitor. For example, selection of a moiety from the list provided for Z, (HO)n, R, R1 and R2 in figure 23 would be acceptable. Alternative ring structures, as illustrated in figures 24 – 28 may be in the species elected but require the selection of a moiety for R and R1. A chemical structure of the elected compound would be useful during the examination process.

Art Unit: 1609

Second Species Election Requirement

Applicant is required to elect a particular composition for the cosmetically or pharmaceutically acceptable delivery system. Applicant should select one cosmetically or pharmaceutically acceptable delivery system from the list in claim 9 or not the cosmetically or pharmaceutically acceptable delivery systems listed in claim 9.

Third Species Election

Applicant is required to elect is the absence or presence of the compounds listed is claim 18. If present, one of the listed groups (e.g., hydroxyl or polyhyrdroxy flavones), a particular combination of the listed groups or not any of the listed groups must be elected.

Fourth Species Election

Applicant must elect if metal ions are present or absent.

Fifth Species Election

Applicant is required to elect if additional skin beneficial ingredients as listed in claim 20 are absent or present. If present, applicant is further required to elect a particular list of ingredients. If anti-inflammatory agents are a component of the elected skin beneficial ingredient composition, then an anti-inflammatory agent listed in claim 22, a particular combination of items from the list in claim 22 or not an anti-inflammatory agent must be elected.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons

Application/Control Number: 10/711,775

Art Unit: 1609

given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to

Application/Control Number: 10/711,775

Art Unit: 1609

petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nissa M. Westerberg whose telephone number is (571) 270-3532. The examiner can normally be reached on M - F, 7:30 a.m. - 5 p.m. ET.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1609

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER

NMW